



Date: 17/05/2022.

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Script Code : 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Script Code : BAJAJHCARE
------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 17th May, 2022 & Submission of financial result.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 17th May, 2022 has considered and approved the following:

- Audited Standalone Financial result for the quarter and year ended 31st March, 2022 along with the Statutory Auditors Report thereon.

A copy of the Audited Financial Results for quarter and year ended March 31, 2022 along with the Statutory Auditor's Report thereon and Declaration required under Regulation 33(3) (d) of SEBI (LODR) Regulation, 2015 are enclosed herewith.

- The Board of Directors have recommended a final dividend of 30% i.e. Rs.1.50/- per equity shares on face value of Rs.5/- each for the financial year ended 31st March, 2022, subject to approval of shareholders in the ensuing Annual General Meeting.
- The re-appointment of Mr. Haresh Sanghvi, Practicing Company Secretary, as Secretarial Auditor of the Company for the Financial Year 2022-23.
- The re-appointment of M/s. Paresh Rakesh & Associates, Chartered Accountant, as Internal Auditor of the Company for the FY 2022-23.
- The re-appointment of V. J. Talati & Co. Cost Accountant, as Cost Auditor of the Company for the FY 2022-23.

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records,

BAJAJ HEALTHCARE LIMITED

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN NO.: L99999MH1993PLC072892




We wish to inform you that Board Meeting commenced today at 01.30 p.m. and concluded at 5.45 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited


Mr. Aakash Keshari
Company Secretary



Encl: as above

BAJAJ HEALTHCARE LIMITED

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN NO.: L99999MH1993PLC072892

Chaturvedi & Agrawal

Chartered Accountants

Independent Auditor's Report on the Quarterly and Year End Audited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

TO
THE BOARD OF DIRECTORS OF
BAJAJ HEALTHCARE LIMITED.

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly and year ended financial results of Bajaj Healthcare Limited (the Company) for the quarter and year ended March 31, 2022 ("the statements"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the statements:

- i. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India of the net profit, other comprehensive income and other financial information for the quarter and year ended March 31, 2022.

Basis for Opinion


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statements have been prepared based on Standalone Financial Statements. The Board of Directors of the Company are responsible for the preparation of these financial results that give a true and fair view of the net profit, other comprehensive income and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Chaturvedi & Agrawal

Chartered Accountants

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial results of the Company to express an opinion on the Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended for March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published



CHATURVEDI & AGRAWAL
Chartered Accountants

unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under Listing regulations.

For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W

Rasik Chaturvedi

Rasik Chaturvedi
Partner

M. no: 039524

UDIN: 22039524AJDDNJ7556

Date: May 17, 2022

Place: Mumbai



BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST March, 2022
(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended	Year Ended
	31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from operations	17,571.36	16,757.49	13,218.16	67,988.98	65,698.38
II. Other Income	44.81	19.81	215.24	144.41	691.26
III. Total Revenue (I+II)	17,616.17	16,777.30	13,433.40	68,133.39	66,389.64
IV. Expenses					
(a) Cost of materials consumed (Including Other Direct Expenses)	14,163.23	8,876.40	8,728.43	49,982.29	46,342.49
(b) Changes in Inventories of Finished Good	(806.20)	3,121.48	(59.94)	(377.00)	70.18
(c) Employee benefits expense	1,086.46	1,130.99	804.61	4,110.87	3,454.87
(d) Finance Costs	448.62	284.47	215.19	1,262.38	829.60
(d) Depreciation and amortisation expense	423.97	485.88	442.88	1,763.66	1,612.42
(e) Other expenses	607.19	545.54	283.03	2,422.72	2,198.12
Total Expenses	15,923.28	14,444.76	10,414.20	59,164.93	54,507.67
V. Profit Before Tax	1,692.89	2,332.54	3,019.20	8,968.46	11,881.97
VI. Tax Expense					
(a) Current tax	385.00	597.00	697.41	2,250.00	3,497.41
(b) Earlier Years #	(360.77)	-	23.73	(358.73)	23.73
(c) Deferred Tax	(78.54)	(8.99)	170.27	(61.40)	49.93
Total Tax Expenses	-54.31	588.01	891.41	1,829.87	3,571.07
VII. Profit (Loss) for the Period	1,747.20	1,744.53	2,127.79	7,138.59	8,310.89
VIII. Other comprehensive Income					
(i) Items that will not be reclassified to profit or loss	9.23	-	(30.46)	9.23	(30.46)
(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.32)	-	8.87	(2.32)	8.87
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the Period	1,754.10	1,744.53	2,106.20	7,145.49	8,289.31
IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	31,468.63	24,461.13
XI. Earnings Per Share (Face Value Rs. 5/-)					
(Not Annualised for Quarter and Year Ended)					
(a) Basic (in Rs.)	6.33	6.32	7.71	25.87	30.11
(b) Diluted (in Rs.)	6.33	6.32	7.71	25.87	30.11

Note :

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on May 17, 2022
- b) The above audited financial results for the Quarter and Year Ended March 31, 2022 have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time issued thereunder, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
- c) The Statement as per IND AS - 108 on segment reporting, the statement of Assets and Liabilities and cash flow are attached.
- d) The Company while filing Income Tax Return for F Y 2020-21 opted to pay Tax as per section 115BAA under New Regime as against the provision in accordance with Old Regime, resulting in refund of Rs. 360.51 lakhs which has been accounted in Earlier Year Tax Expenses.
- e) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification based on notified Schedule III Division II of the Act.
- f) Pursuant to the approval of the shareholders by way of Postal Ballot on September 17, 2021, each Equity Share of Rs. 10/- each fully paid up was subdivided into 2 Equity Shares of Rs. 5/- each fully paid up, with effect from the record date September 29, 2021. Consequently, the basic and diluted earnings per share have been adjusted retrospectively for all the periods presented in the Standalone Financial Results of the Company on the basis of the new number of equity shares in accordance with the provisions of applicable Ind AS.
- g) The Figures for quarter ended March 31, 2022 and March 31, 2021 are balancing figure between audited figures of full financial year and published unaudited figures upto the third quarter of the respective financial years
- h) The Board of Directors have recommended a Final dividend of 30% (i.e. Rs. 1.50/- Only) per equity share on the face value of Rs. 5/- each for the financial year ended 31st March 2022, subject to approval of shareholders in the ensuing Annual General Meeting.

By Order of the Board
For Bajaj Healthcare Limited

Anil Jain
Jt. Managing Director
DIN : 00226137



Date: 17th May 2022
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)


Statement Of Assets & Liabilities As At March 31, 2022

(Rs in Lakhs)

Particulars	As at	As at
	March 31, 2022	March 31, 2021
	(Audited)	(Audited)
ASSETS		
Non-current assets		
(a) Property Plant & Equipment	26,974.03	20,812.77
(b) Capital work-In-progress	5,197.58	5,704.75
(c) Financial Assets		
(i) Long Term Investments	0.31	0.31
(ii) Other Financial assets	107.39	212.04
Current assets		
(a) Inventories	15,926.18	9,711.03
(b) Financial Assets		
(i) Trade receivables	18,451.18	9,888.28
(ii) Cash and cash equivalents	197.50	1,424.11
(iii) Other Financial assets	1,101.58	66.33
Other Current assets	4,154.60	4,743.56
TOTAL ASSETS	72,110.34	52,563.17
EQUITY AND LIABILITIES		
Equity		
(a) Share Capital	1,379.92	1,379.92
(b) Other Equity	31,468.63	24,461.13
Sub - Total - Equity	32,848.55	25,841.05
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(a) Borrowings	6,631.00	7,971.33
Deffered Tax Liabilities	156.32	215.40
Long-term Provisions	267.17	278.06
Current Liabilities		
Financial Liabilities		
(a) Trade payables	10,492.01	6,895.37
(b) Borrowings	19,042.57	10,117.24
(c) Other Financial liabilities	1,605.14	1,077.64
Other Current Liabilities	116.55	149.29
Provisions	22.88	17.79
Current Tax Liabilities	928.15	-
TOTAL - EQUITY AND LIABILITIES	72,110.34	52,563.17

By Order of the Board
For Bajaj Healthcare Limited


Anil Jain
Jt. Managing Director
DIN : 00226137



Date: 17th May 2022

Place: Thane

Bajaj Healthcare Limited
Cash Flow Statement for the Year ended March 31, 2022
CIN: L99999MH1993PLC072892

Sr No	Particulars	Amt (Rs. In Lakhs)	
		Year Ended March 31, 2022	Year Ended March 31, 2021
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit Before Tax		8,968.46
	Adjustments for:		
	Depreciation	1,763.66	1,612.42
	(Profit)/loss on sale of Assets	1.21	(1.16)
	Interest & Finance Charges	1,262.38	829.60
	Interest on FD	(17.17)	(16.69)
	Provision for Employee Benefits & Leave Enchashment	95.62	99.64
	ECL Provision	41.51	(75.63)
		3,147.22	2,448.18
	Operating Profit before Working Capital Changes	12,115.68	14,330.15
	Adjustments for:		
	(Increase)/Decrease in Other current assets	(341.64)	(2,187.37)
	(increase)/Decrease in Sundry Debtors	(8,604.41)	35.12
	(Increase)/Decrease In Inventories	(6,215.15)	(5,783.52)
Increase /(Decrease) in non current and current liabilities	4,077.24	1,526.59	
	(11,083.96)	(6,409.18)	
Cash generated from operations	1,031.72	7,920.97	
Income Tax Paid	(963.12)	(3,565.14)	
Net Cash flow from Operating activities	68.60	4,355.83	
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	(7,930.49)	(6,218.72)
	(Increase)/Decrease in Capital Wip	507.17	(5,160.15)
	Sale Of Fixed Assets	4.35	18.96
	Interest on FD	17.17	16.69
	Payment to Gratuity Fund	(78.03)	(50.08)
	Investment in Preference Shares	-	500.00
Net Cash used in Investing activities	(7,479.83)	(10,893.30)	
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Increase /(Decrease) From Long Term Borrowing	(1,188.24)	5,673.94
	Increase /(Decrease) Of Unsecured Long Term Borrowing	-	(60.43)
	Increase /(Decrease) Of Short Term Borrowing From Bank	8,612.90	3,043.16
	Increase /(Decrease) Of Borrowing From Director & Inter corpates	160.35	(39.86)
	Interest paid	(1,262.38)	(829.60)
	Dividend Paid	(137.99)	(241.49)
Net Cash used in financing activities	6,184.63	7,545.73	
	(1,226.60)	1,008.26	
	1,424.11	415.85	
	197.50	1,424.11	

Place: Thane
Date: 17th May 2022

By Order of the Board
For Bajaj Healthcare Limited

Anil Jain
Jt. Managing Director
DIN : 00226137



BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH11993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER AND YEAR ENDED ON 31ST MARCH, 2022

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Year ended	Year Ended
		31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
A	Segment Revenue (Excluding Intersegment Revenue)					
	Bulk Drugs	15901.83	15906.58	12723.88	59078.18	59336.46
	Formulations	1669.53	850.91	494.28	8910.80	6361.92
	Total	17,571.37	16,757.49	13,218.16	67,988.98	65,698.38
	Inter Segments/ Units Revenue					
	Bulk Drugs	2036.21	1,423.53	271.17	9,393.30	2,586.87
	Formulations	0.07	-	170.10	615.18	210.83
	Total	2,036.27	1,423.53	441.27	10,008.49	2,797.69
	Gross Segment Revenue (Including Intersegment Revenue)					
	Bulk Drugs	17938.04	17330.11	12995.05	68471.48	61923.32
	Formulations	1669.60	850.91	664.38	9525.99	6572.75
	Total	19,607.64	18,181.02	13,659.43	77,997.47	68,496.07
B	II. Segment Results					
	Profit / (Loss) Before Tax & Finance Cost					
	Bulk Drugs	2505.88	2,954.81	3,445.83	11,804.73	13,924.25
	Formulations	242.82	207.74	11.99	848.84	985.43
	Total	2,748.70	3,162.55	3,457.82	12,653.57	14,909.68
Less : Interest	448.63	284.47	215.18	1,262.38	829.60	
Other Unallocable Expenditure (Net)	607.19	545.54	223.43	2,422.72	2,198.12	
Total Profit Before Tax	1,692.88	2,332.54	3,019.21	8,968.46	11,881.97	
C	I. Segment Assets					
	Bulk Drugs	65,107.84	64,651.38	50,063.51	65,107.84	50,063.51
	Formulations	7,002.20	5,670.49	2,499.35	7,002.20	2,499.35
	Others	0.31	0.31	0.31	0.31	0.31
	Total	72,110.34	70,322.18	52,563.17	72,110.34	52,563.17
	II. Segment Liabilities					
	Bulk Drugs	37,365.10	37,888.37	25,743.74	37,365.10	25,743.74
	Formulations	1,450.32	825.71	484.92	1,450.32	484.92
	Others	446.36	513.64	493.46	446.36	493.46
	Total	39,261.79	39,227.73	26,722.12	39,261.79	26,722.12
Total Capital Employed	32,848.55	31,094.45	25,841.05	32,848.55	25,841.05	
Total (II+III)	72,110.34	70,322.18	52,563.17	72,110.34	52,563.17	

Place : Thane
Date : 17th May 2022

By Order of the Board
For Bajaj Healthcare Limited

Anil Jain
Jt. Managing Director
DIN : 00226137





Date: 17/05/2022.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I, Rupesh H. Nikam, Chief Financial Officer of Bajaj Healthcare Limited (CIN: L99999MH1993PLC072892) having its registered office at 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West Thane- 400604 hereby declare that the Statutory Auditors of the Company M/s. Chaturvedi & Agrawal, Chartered Accountants (Firm Registration No. 101717W) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company (Standalone) for the year ended March, 31, 2021.

This disclosure is given in compliance to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations) 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations 2016 vide Notification no. SEBI/LAD/NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May, 27, 2016.

Kindly take this declaration on your records.

Thanking you.

Yours faithfully,

For Bajaj Healthcare Limited

Mr. Rupesh Nikam
Chief Financial Officer



BAJAJ HEALTHCARE LIMITED

Registered Office : Corp. Off.: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A/1, Road No. 23, Above ICICI Bank, Wagle Ind. Estate, Thane(W)-400604.

• Tel. : +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN NO.: L99999MH1993PLC072892